BSE Live
Mar 25, 16:01Prev. Close
242.00
Open Price
239.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 25, 15:51Prev. Close
243.10
Open Price
244.00
Bid Price (Qty.)
237.65 (51)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Wanbury (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 29.55 | 30.78 | -10.29 | 81.13 | -12.41 | |
| Net CashFlow From Operating Activities | 26.10 | 4.02 | 19.80 | 40.52 | 16.68 | |
| Net Cash Used In Investing Activities | -51.17 | -16.63 | -8.84 | 0.59 | 8.04 | |
| Net Cash Used From Financing Activities | 25.73 | 14.55 | -31.99 | -28.58 | -17.39 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 0.66 | 1.94 | -21.03 | 12.53 | 7.34 | |
| Cash And Cash Equivalents Begin of Year | 3.94 | 1.46 | 22.49 | 9.96 | 2.62 | |
| Cash And Cash Equivalents End Of Year | 4.60 | 3.40 | 1.46 | 22.49 | 9.96 |
10.02.2026
Wanbury Standalone December 2025 Net Sales at Rs 162.45 crore, up 21.73% Y-o-Y
24.11.2025
Wanbury Standalone September 2025 Net Sales at Rs 160.06 crore, down 0.7% Y-o-Y
12.08.2025
Wanbury Consolidated June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
05.08.2025
Wanbury Standalone June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
10.02.2026
Wanbury Standalone December 2025 Net Sales at Rs 162.45 crore, up 21.73% Y-o-Y
24.11.2025
Wanbury Standalone September 2025 Net Sales at Rs 160.06 crore, down 0.7% Y-o-Y
12.08.2025
Wanbury Consolidated June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
05.08.2025
Wanbury Standalone June 2025 Net Sales at Rs 163.18 crore, up 24.47% Y-o-Y
25.03.2026
25.03.2026
25.03.2026
24.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth